Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

VBI Vaccines : Announces First Quarter 2020 Financial Results and Provides Corporate Update

share with twitter share with LinkedIn share with facebook
05/06/2020 | 08:19am EDT
  • Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
  • Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS - human clinical study material expected to be available in Q4 2020
  • Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
  • Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
  • Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the first quarter ending March 31, 2020 and provided a corporate update.

President and CEO, Jeff Baxter, commented, 'The last several months have brought unprecedented public health and societal challenges. Science and technology are at the forefront of everyone's mind, and since the outbreak of COVID-19 there has been a renewed interest in the vaccine space. An effective COVID-19 vaccine is vital to enabling the return to normalcy. We need the collaboration of many great minds to solve this crisis, and we are aggressively working to be part of the solution with our recently announced pan-coronavirus vaccine candidate. Our candidate, VBI-2901, co-expresses SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins in a multivalent construct that could allow for the production of broadly reactive antibodies, which may also offer potential protection from mutated strains of COVID-19 that may emerge over time. In collaboration with the National Research Council of Canada (NRC), we are evaluating and selecting the optimal vaccine candidate, with the goal of having clinical study material available in Q4 2020. Additionally, we aim to provide periodic updates on the candidate development throughout 2020.

'In this time of heightened public health focus and awareness, we continue to fire on all cylinders as we work to address other significant public health needs. Following the successful completion of the pivotal Phase 3 program for Sci-B-Vac®, our tri-antigenic prophylactic hepatitis B vaccine, we are working with the FDA, EMA, and Health Canada to prepare for submissions of regulatory approval applications in the U.S., Europe, and Canada, beginning in the fourth quarter of 2020. Additionally, the clinical trials for our hepatitis B immunotherapeutic and our glioblastoma (GBM) cancer vaccine immunotherapeutic candidates have not yet been materially impacted by the COVID-19 pandemic and are currently on-track for their respective clinical data readouts expected later in 2020.

'We have been working hard to ensure the safety and health of all employees while also continuing to achieve key program milestones. This balance has required tremendous dedication, flexibility, and communication from every member of the VBI team. With net proceeds of approximately $54 million from our recent equity raise added to the balance sheet, we believe we are now well-positioned to capitalize on the growth and value-driving opportunities ahead.'

Recent Highlights and Upcoming Program Milestones

Equity Financing

  • April 2020: $57.5 million of gross proceeds raised in an underwritten public offering, resulting in net cash proceeds to the company of approximately $54 million.

Appointment of New Board Member

  • March 2020: Damian Braga, former Senior Vice President, Global Commercial Operations and President, U.S. and the Americas, of Sanofi Pasteur, joined VBI's Board of Directors.

Sci-B-Vac®: Tri-antigenic Prophylactic Hepatitis B (HBV) Vaccine

  • January 2020: Positive top-line results from second pivotal Phase 3 study, CONSTANT, demonstrated lot-to-lot manufacturing consistency, high seroprotection rates and antibody titers, safety and tolerability.
  • Q2 2020: Pre-BLA discussions expected with the FDA.
  • Q4 2020: Submission of applications for regulatory approvals in the U.S., Europe, and Canada expected to begin.

VBI-2601 (BRII-179): HBV Immunotherapeutic Candidate

  • H2 2020: Initial human proof-of-concept data expected from Phase 1b/2a study.

VBI-1901: Cancer Vaccine Immunotherapeutic Candidate

  • February 2020: Dosing of the 10 patients in the VBI-1901 + GSK's AS01B adjuvant system study arm began.
  • March 2020: Overall survival (OS) data from Part A VBI-1901 + GM-CSF study arm demonstrated 12-month OS rates of 83% (n=5/6) among vaccine responders vs. 33% (n=3/9) for vaccine non-responders, and a 6.25-month improvement in median OS among vaccine responders (14.0 months) vs. non-responders (7.75 months).
  • April 2020: Based upon review of safety data from the first three patients enrolled, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended continuation of the Phase 2a VBI-1901 + AS01B study arm without modification.
  • Mid-year 2020: Expanded immunologic, tumor, and clinical data expected from the Phase 2a VBI-1901 + GM-CSF study arm.
  • Q4 2020: Initial immunologic and tumor response data expected from the Phase 2a VBI-1901 + AS01B study arm.

VBI-2901: Trivalent Prophylactic Pan-Coronavirus Candidate

  • March 2020: As part of a collaboration with the NRC, preclinical development began on a pan-coronavirus vaccine targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
  • Q2 2020: IND-enabling pre-clinical animal models expected to begin.
  • Q4 2020: Clinical study materials expected to be available for clinical studies.

First Quarter 2020 Financial Results

  • Cash Position: VBI ended the first quarter of 2020 with $35.8 million in cash and cash equivalents compared to $44.2 million as of December 31, 2019. Cash position at March 31, 2020, does not include approximately $54 million of net cash proceeds from the April 2020 underwritten public offering.
  • Net Cash Used in Operating Activities: Net cash used in operations for the three months ended March 31, 2020 was $7.6 million compared to $14.0 million for the same period in 2019. This decrease was due to completion of the Sci-B-Vac® Phase 3 clinical studies.
  • Cash Used for Purchase of Property and Equipment: Cash used for the purchase of property and equipment was $0.1 million for the three months ended March 31, 2020 compared to $1.9 million for the same period in 2019. The difference is due to capital purchases and replacements related to the modernization and capacity increases of our manufacturing facility in Rehovot, Israel, that occurred in the first quarter of 2019. The modernization and capacity increases were completed in May 2019.
  • Revenue: Revenue in the first quarter of 2020 was $0.42 million, compared to $0.36 million for the same period in 2019. This increase was due to an increase in named-patient sales of Sci-B-Vac® in Europe.
  • Cost of Revenues: Cost of Revenues was $2.6 million for the first quarter of 2020 compared to $1.2 million in the same period of 2019. The increase is due to re-commencement of manufacturing at the facility in Rehovot and the related costs.
  • Research and Development (R&D): R&D expenses were $3.2 million for the first quarter of 2020, compared to $9.0 million for the same period in 2019. The decrease in R&D expenses is the result of the decrease in costs related to the Sci-B-Vac® Phase 3 clinical studies, the first of which (PROTECT) completed in June 2019, the second of which (CONSTANT) completed in January 2020.
  • General and Administrative (G&A): G&A expenses were $4.1 million for the first quarter of 2020, compared to $4.0 million for the same period in 2019. This slight increase is due to the increase in pre-commercial activities for Sci-B-Vac®, but is largely offset by the allocation of certain cost of revenues, related to the temporary closure of the Rehovot facility, in the first quarter of 2019 that did not reoccur during the first quarter of 2020.
  • Net Loss: Net loss and net loss per share for the first quarter of 2020 were $8.4 million and $0.05, respectively, compared to a net loss of $14.6 million and a net loss per share of $0.15 for the first quarter of 2019.
About VBI Vaccines

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only tri-antigenic hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

VBI Investor and Media Contact

Nicole Anderson
Director, Corporate Communications & IR
Phone: (617) 830-3031 x124
Email: ir@vbivaccines.com

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, 'forward-looking statements'). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the recent COVID-19 outbreak on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

Disclaimer

VBI Vaccines Inc. published this content on 06 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2020 12:18:13 UTC

share with twitter share with LinkedIn share with facebook
Latest news on VBI VACCINES INC.
06/22VBI-1901 : AACR Data, Partial Response and Biomarker Strategy
PU
06/22VBI-1901 : AACR Data and Clinical Update
PU
06/22VBI VACCINES ANNOUNCES DATA FROM VBI : Partial Response Observed, Promising Biom..
BU
06/18VBI VACCINES : Announces Results of Annual General Meeting
BU
06/17VBI VACCINES : to Present at Upcoming Investor Conferences
BU
05/28VBI VACCINES : Announces Formation of Commercial Advisory Board
BU
05/27VBI VACCINES : Secures $50 Million Debt Financing From K2 HealthVentures
BU
05/21VBI-2901 : Pan-Coronavirus Vaccine Candidate Overview
PU
05/15VBI VACCINES : Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-..
BU
05/15Hedge Funds Expect a Cure But Are Wary of Betting Big -- WSJ
DJ
More news
Financials (USD)
Sales 2020 2,64 M - -
Net income 2020 -45,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -13,9x
Yield 2020 -
Capitalization 662 M 662 M -
EV / Sales 2019
Capi. / Sales 2020 251x
Nbr of Employees -
Free-Float 71,5%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 4,50 $
Last Close Price 2,87 $
Spread / Highest target 179%
Spread / Average Target 56,8%
Spread / Lowest Target 4,53%
EPS Revisions
Managers
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Steven H. Gillis Chairman
Christopher McNulty CFO, Director & Head-Business Development
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.107.97%662
LONZA GROUP45.13%40 295
CELLTRION, INC.70.99%34 505
SEATTLE GENETICS, INC.47.93%29 259
IQVIA HOLDINGS INC.-8.41%27 025
INCYTE CORPORATION21.93%23 144